Conference item
Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients.
- Abstract:
-
BACKGROUND: The safety of any immune modulating agent in type 1 diabetes mellitus (T1DM) involves its selectivity on autoimmunity and its preservation of recall and tumour immunity. METHODS: We performed lymphocyte proliferation tests on seven recent onset diabetic patients treated with anti-CD3 (Otelixizumab; ChAglyCD3) and five recent onset diabetic patients treated with placebo, on average 2 years after therapy. RESULTS: Proliferative responses towards common viral, bacterial and yeast an...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Volume:
- 27
- Issue:
- 8
- Pages:
- 925-927
- Host title:
- Diabetes/metabolism research and reviews
- Publication date:
- 2011-11-01
- Event location:
- England
- DOI:
- EISSN:
-
1520-7560
- ISSN:
-
1520-7552
- Source identifiers:
-
314350
Item Description
- Keywords:
- Pubs id:
-
pubs:314350
- UUID:
-
uuid:68c9823a-c957-4280-9669-a6adc46eaae8
- Local pid:
- pubs:314350
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2011
If you are the owner of this record, you can report an update to it here: Report update to this record